Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2567-2575

  Roberson, Peter L ^a   Dudek, Stephen ^a   Buchsbaum, Donald J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

131I labeled monoclonal antibodies; Beta dosimetry; Dosimetry; Effective dose; Fractionation; Radioimmunotherapy; Serial section autoradiography

Indexed keywords

MONOCLONAL ANTIBODY I 131;

ANIMAL EXPERIMENT; ANIMAL MODEL; BOLUS INJECTION; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CELL PROLIFERATION; COLON CANCER; CONFERENCE PAPER; CONTINUOUS INFUSION; DOSE CALCULATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 0031444160     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2567::aid-cncr32>3.0.co;2-8     Document Type: Conference Paper

References (29)

1. Schlom J, Molinolo A, Simpson JF, Siler K, Roselli M, Hinkle G, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990;82:763-71.
2. 131I-labeled monoclonal antibody CC49. Cancer Res 1995;55(suppl):5881-7.
3. Adams GP, McCartney JE, Wolf EJ, Eisenberg J, Tai MS, Huston JS, et al. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration. Cancer Immunol Immunother 1995;40:299-306.
4. Knox SJ, Goris ML, Wessels BW. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol 1992;23:111-7.
5. 131Iodine-labeled antibody for a colon cancer model. Cancer Res 1995;55(suppl):5811-6.
6. Wessels BW, Vessella RL, Palme DF, Berkopec JM, Smith GK, Bradley EW. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 1989;17:1257-63.
7. Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992; 52:1067-72.
8. Roberson PL, Buchsbaum DJ, Heidorn DB, Ten Haken RK. Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography. Int J Radiat Oncol Biol Phys 1992;24:329-34.
9. Prestwich WV, Nunes J, Kwok CS. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J Nucl Med 1989;30:1036-46, 1739-40.
10. Roberson PL, Heidorn DB, Kessler ML, Ten Haken RK, Buchsbaum DJ. Three-dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose-rate nonuniformity. Cancer 1994;73:912-8.
11. 131iodine-labeled monoclonal antibodies. Antibody Immunoconjug Radiopharmacol 1992;5:397-402.
12. Esteban JM, Schlom J, Mornex F, Colcher D. Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Eur J Cancer Clin Oncol 1987;23:643-55.
13. Roberson PL, Buchsbaum DJ. Comparison of 3D tumor dose distributions for CC49 and 17-1A monoclonal antibodies. Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, TN, May 1996.
14. Loevinger R, Burman M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. Medical Internal Radiation Dose Pamphlet, no. 1, revised. New York: Society of Nuclear Medicine, 1976.
15. Millar WT. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. Br J Radiol 1991;64:242-51.
16. Hall EJ. Radiobiology for the radiologist. Philadelphia: JB Lippincott, 1988.
17. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990;18:1261-9.
18. Wong JYC, Williams LE, Demidecki AJ, Wessels BW, Yan XW. Radiobiologic studies comparing yttrium-90 irradiation and external beam irradiation in vitro. Int J Radiat Oncol Biol Phys 1991;20:715-22.
19. 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 1990;18:1033-41.
20. Leith JT, Padfield G, Faulkner L, Michelson S. Hypoxic fractions in xenografted human colon tumors. Cancer Res 1991;51:5139-43.
21. Siegel JA, Wessels BW, Watson EE, Stabin MG, Vriesendoerp HM Bradley EW, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharmacol 1990;3:213-33.
22. Muthuswamy MS, Roberson PL, Ten Haken RK, Buchsbaum DJ. A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography. Int J Radiat Oncol Biol Phys 1996;35:165-72.
23. Muthuswamy MS, Roberson PL, Buchsbaum DJ. A mouse bone marrow dosimetry model [abstract]. Med Phys 1996;23:1090.
24. Hendry JH, Schofield R, Bwire NEB. Radiosensitivity of murine hemopoietic colony-forming units assayed in situ in the rib and in other marrow sites. Radiat Res 1986;105:370-8.
25. Tarbell NJ, Amato DA, Down JD, Mauch P, Hellman S. Fractionation and dose rate effects in mice: a model for bone marrow transplantation in man. Int J Radiat Oncol Biol Phys 1987;13:1065-69.
26. Blumenthal RD, Sharkey RM, Forman D, Wong G, Hess J, Goldenberg DM. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp Hematol 1995;23:1088-97.
27. Goddu SM, Howell RW, Rao DV. Generalized approach to absorbed dose calculations for dynamic tumor and organ masses. J Nucl Med 1995;36:1923-7.
28. Howell RW, Rao DV. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. Med Phys 1989;16:66-74.
29. Blumenthal RD, Kashi R, Sharky RM, Goldenberg DM. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int J Cancer 1995;61:557-66.